Medigen Vaccine Biologics (6547) — Cash Flow Quality Index
Medigen Vaccine Biologics (6547) has a Cash Flow Quality Index of 2.69x as of September 2024. Operating cash flow of NT$4.05 Million exceeds net income of NT$1.51 Million, indicating high earnings quality where cash backs reported profits. Also explore Medigen Vaccine Biologics asset portfolio for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Medigen Vaccine Biologics Cash Flow Quality Index (2021–2021)
Historical Cash Flow Quality Index for Medigen Vaccine Biologics across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Medigen Vaccine Biologics (6547) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Medigen Vaccine Biologics (2021–2021)
Year-by-year earnings quality comparison for Medigen Vaccine Biologics. For live market cap and the full company financial profile, see 6547 stock market capitalisation.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 0.41x | NT$579.89 Million | NT$1.41 Billion | — |